Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial.

Autor: Keil F; 3rd Medical Department for Haematology and Oncology, Hanusch Hospital, Vienna, Austria., Müller AMS; Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria.; Department of Medical Oncology and Haematology, University Hospital Zurich, Zurich, Switzerland., Berghold A; Institute for Medical Informatics, Statistics, and Documentation, Medical University Graz, Graz, Austria., Riedl R; Institute for Medical Informatics, Statistics, and Documentation, Medical University Graz, Graz, Austria., Buxhofer-Ausch V; Department of Internal Medicine I with Haematology, Stem Cell Transplantation, Haemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria.; Medical Faculty, Johannes Kepler University Linz, Linz, Austria., Schuster J; Austrian Group Medical Tumor Therapy (AGMT), Salzburg, Austria., Vorburger C; Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland., Böhm A; Haematological Health Care Centre of the ÖGK Mariahilf, Vienna, Austria., Panny M; 3rd Medical Department for Haematology and Oncology, Hanusch Hospital, Vienna, Austria., Nösslinger T; 3rd Medical Department for Haematology and Oncology, Hanusch Hospital, Vienna, Austria., Greil R; Austrian Group Medical Tumor Therapy (AGMT), Salzburg, Austria.; Cancer Cluster Salzburg (CCS), Salzburg, Austria.; III Medical Department with Haematology and Medical Oncology, Haemostaseology, Rheumatology and Infectious Diseases, Oncologic Centre, Paracelsus Medical University, Salzburg, Austria.; Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Centre for Clinical Cancer and Immunology Trials (CCCIT), Salzburg, Austria., Samaras P; Clinic for Haematology and Oncology Hirslanden Zurich, Zurich, Switzerland., Bencker C; 3rd Medical Department for Haematology and Oncology, Hanusch Hospital, Vienna, Austria., Rütti M; Department of Medical Oncology and Haematology, University Hospital Zurich, Zurich, Switzerland., Pabst T; Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.

Publikováno v: EClinicalMedicine [EClinicalMedicine] 2023 Nov 19; Vol. 66, pp. 102318. Date of Electronic Publication: 2023 Nov 19 (Print Publication: 2023).

Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation.

Autor: Bankova AK; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland., Pasin C; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland., Huang A; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland., Cicin-Sain C; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland., Epp S; Institute of Medical Virology, University of Zürich, Zürich, Switzerland., Audige A; Institute of Medical Virology, University of Zürich, Zürich, Switzerland., Mueller NJ; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland., Nilsson J; Department of Immunology, University Hospital Zürich, Zürich, Switzerland., Vilinovszki O; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.; Department of Internal Medicine, University Hospital Zürich, Zürich, Switzerland., Nair G; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland., Wolfensberger N; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland., Hockl P; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland., Schanz U; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland., Trkola A; Institute of Medical Virology, University of Zürich, Zürich, Switzerland., Kouyos R; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland., Hasse B; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland., Zinkernagel AS; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland., Manz MG; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland., Abela IA; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland., Müller AMS; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.; Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.

Publikováno v: British journal of haematology [Br J Haematol] 2023 Apr; Vol. 201 (1), pp. 58-63. Date of Electronic Publication: 2022 Nov 16.